Comparison of the effects of angiotensin receptor-neprilysin inhibitors and thiazide diuretic/renin-angiotensin system inhibitor combination therapy in hypertensive patients : a retrospective cohort study
© 2023. The Author(s), under exclusive licence to Springer Nature Limited..
Angiotensin receptor-neprilysin inhibitors (ARNIs) have been approved as antihypertensive agents in Japan, and thiazide diuretics (TZDs) are widely used concomitantly with renin-angiotensin system inhibitors (RASIs) for hypertension. This retrospective study included patients with hypertension who switched from RASI to ARNI therapy (ARNI group) and those who were prescribed TZDs with RASIs (TZD/RASI group). Drug-related changes in the estimated glomerular filtration rate (eGFR), blood pressure (BP), body weight (BW), serum electrolytes, uric acid (UA), and triglyceride levels were compared between the two groups. Overall, 70 participants (31 and 39 in the ARNI and TZD/RASI groups, respectively) were enrolled and observed for a median of 2 months. According to linear mixed models, compared with the TZD/RASI group, the ARNI group exhibited a significant change in mean eGFR of 3.71 mL/min/1.73 m2 [95% confidence interval (CI), 0.57-6.84; P = 0.02] from the time of switching drug to the next outpatient visit. Further, compared with the TZD/RASI group, the ARNI group exhibited significant changes in mean serum UA (-1.27; 95% CI, -1.66 to -0.88), sodium (1.22; 95% CI, 0.12 to -2.32), chloride (2.14; 95% CI, 0.75-3.52), and triglyceride (-52.1; 95% CI, -100.9 to -3.29) levels. Conversely, serum potassium levels, BW, and systolic and diastolic BP did not differ significantly between the two groups (P = 0.69, 0.44, 0.49, and 0.66, respectively). Compared with the combination therapy of TZD and RASI, ARNI therapy causes less renal dysfunction, hyperuricemia, and hypertriglyceridemia with fewer electrolyte abnormalities and no significant difference in antihypertensive effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of human hypertension - 37(2023), 12 vom: 26. Dez., Seite 1049-1055 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitsuno, Ryunosuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 11.01.2024 Date Revised 11.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41371-023-00851-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35988489X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35988489X | ||
| 003 | DE-627 | ||
| 005 | 20240114233733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41371-023-00851-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM35988489X | ||
| 035 | |a (NLM)37488277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitsuno, Ryunosuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the effects of angiotensin receptor-neprilysin inhibitors and thiazide diuretic/renin-angiotensin system inhibitor combination therapy in hypertensive patients |b a retrospective cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2024 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Angiotensin receptor-neprilysin inhibitors (ARNIs) have been approved as antihypertensive agents in Japan, and thiazide diuretics (TZDs) are widely used concomitantly with renin-angiotensin system inhibitors (RASIs) for hypertension. This retrospective study included patients with hypertension who switched from RASI to ARNI therapy (ARNI group) and those who were prescribed TZDs with RASIs (TZD/RASI group). Drug-related changes in the estimated glomerular filtration rate (eGFR), blood pressure (BP), body weight (BW), serum electrolytes, uric acid (UA), and triglyceride levels were compared between the two groups. Overall, 70 participants (31 and 39 in the ARNI and TZD/RASI groups, respectively) were enrolled and observed for a median of 2 months. According to linear mixed models, compared with the TZD/RASI group, the ARNI group exhibited a significant change in mean eGFR of 3.71 mL/min/1.73 m2 [95% confidence interval (CI), 0.57-6.84; P = 0.02] from the time of switching drug to the next outpatient visit. Further, compared with the TZD/RASI group, the ARNI group exhibited significant changes in mean serum UA (-1.27; 95% CI, -1.66 to -0.88), sodium (1.22; 95% CI, 0.12 to -2.32), chloride (2.14; 95% CI, 0.75-3.52), and triglyceride (-52.1; 95% CI, -100.9 to -3.29) levels. Conversely, serum potassium levels, BW, and systolic and diastolic BP did not differ significantly between the two groups (P = 0.69, 0.44, 0.49, and 0.66, respectively). Compared with the combination therapy of TZD and RASI, ARNI therapy causes less renal dysfunction, hyperuricemia, and hypertriglyceridemia with fewer electrolyte abnormalities and no significant difference in antihypertensive effects | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Neprilysin |2 NLM | |
| 650 | 7 | |a EC 3.4.24.11 |2 NLM | |
| 650 | 7 | |a Receptors, Angiotensin |2 NLM | |
| 650 | 7 | |a Sodium Chloride Symporter Inhibitors |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 700 | 1 | |a Uchiyama, Kiyotaka |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Takashin |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Rina |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimoto, Norifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Shintaro |e verfasserin |4 aut | |
| 700 | 1 | |a Washida, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of human hypertension |d 1996 |g 37(2023), 12 vom: 26. Dez., Seite 1049-1055 |w (DE-627)NLM012646121 |x 1476-5527 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:12 |g day:26 |g month:12 |g pages:1049-1055 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41371-023-00851-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 12 |b 26 |c 12 |h 1049-1055 | ||